Secondary Logo

Journal Logo


A rare pediatric renal tumor: classic congenital mesoblastic nephroma two cases and review of literature

Bendre, Pradnya S.; Dsouza, Flavia H.; Multani, Pooja V.

Author Information
doi: 10.1097/01.XPS.0000452061.53568.79
  • Free



Congenital mesoblastic nephroma (CMN) is a rare renal tumor, with an incidence of 3.5% of all renal tumors 1. Glick et al.2 studied 101 renal tumors, of which 11 occurred at the age of 6 months or less, with CMN occurring in seven cases. In 1967, Bolande et al.3 described CMN as a separate entity from congenital Wilms’ tumor and emphasized on its benign nature 4. The CMN generally presents as an asymptomatic abdominal mass, sometimes accompanied by hematuria. It can also have varied presentation because of paraneoplastic syndromes. With the advancement in technology, antenatal diagnosis is not unknown when it can lead to polyhydramnios (71% of the gestations associated with the tumor), hydrops, and premature delivery, in addition to hypertension and hypercalcemia (owing to the tumor’s secretion of a substance similar to parathormone) 5,6. Nephrectomy is the treatment of choice and is alone sufficient for good survival.

Patients and methods

Case 1

A 2-month-old male child presented with progressively increasing abdominal mass. An abdominal ultrasound (USG) scan revealed an echogenic mass in the upper pole of the right kidney, with its outer part showing concentric hyperechoic and hypoechoic layering, and the center was of slightly lower echogenicity (ring sign). The lower pole of the right kidney, left kidney, and adrenals were normal. Computed tomographic (CT) scan of the abdomen confirmed the presence of a low attenuation mass in the upper pole of the right kidney, measuring 9.3×3×3 cm (Fig. 1). The right renal artery was stretched around the inferior part of the mass. CT scan of the chest was normal.

Fig. 1
Fig. 1:
Computed tomographic scan showing huge mass.

The hemogram, serum electrolytes, coagulation profile, and creatinine were normal. Ionized calcium was borderline high, initially at 1.39 mmol/l (0.9–1.3 mmol/l), but repeat samples were within normal range. A right nephrectomy with hilar and caval node excision was performed.

The pathological findings were consistent with classic CMN. The patient is now 2 years old and is asymptomatic. Follow-up USG of these two patients showed no recurrence.

Case 2

A 3-month-old male child presented with incidentally detected abdominal lump and hypertension. On examination, the child was hypertensive and routine blood investigations were normal. USG and CT scan revealed mass arising from the upper pole of the right kidney. Blood pressure was controlled and the child underwent right nephrectomy (Fig. 2). On gross, the tumor was ill-defined with no obvious capsule (Fig. 3). Microscopy showed spindle cells and no atypia and was suggestive of classic CMN (Fig. 4). Postoperative antihypertensive medication was required for 2 weeks. The child is now doing well at 2-year follow-up.

Fig. 2
Fig. 2:
Intraoperative removal.
Fig. 3
Fig. 3:
Gross appearance with no identified capsule.
Fig. 4
Fig. 4:
Microscopy showing classic congenital mesoblastic nephroma.

Follow-up protocol at our institute for renal tumors was carried out by pediatric oncologists. Close surveillance was done in the first year by 3-monthly USG, and later on by 6–12-monthly USG. CT scan was repeated only when USG showed recurrence. Regular blood pressure was monitored for tapering and stopping antihypertensive medication.


The vast majority of renal tumors encountered in infancy are benign, representing mesenchymal hamartomatous maldevelopment of the fetal kidney. In the older literature (before 1975), leiomyomatous hamartoma and fetal renal hamartomas were used synonymously with CMN 7.

Although CMN is a rare tumor, it is the most common renal tumor under 6 months of age and constitutes 3.4% of all renal tumors 8. Of the cases with CMN, 67% have hypertension at presentation. Hypertension in CMN has been explained on the basis of hyperreninemia, which is seen in 80% of the cases of CMN. Overproduction of renin may be primary, that is, it is secreted in the tumor, or secondary because of ischemia of the renal tissue from compression by the tumor, which is more likely in the leiomyomatous type 9–11.

Although the most common presentation is an asymptomatic abdominal mass, other clinical features include hematuria, proteinuria, polyuria, vomiting, hypercalcemia, jaundice, dehydration, azotemia, and electrolyte disturbances 11. None of these were seen in our patient association of Von Willebrand disease, which has also been reported 12.

Imaging plays an important role not only in the detection of renal tumors but also in the process of differential diagnosis. Cystic renal masses are well delineated by ultrasonography; however, solid lesions may require further evaluation by CT or MRI 13. On USG imaging, CMN appears typically as a well-defined, solid, homogeneous lesion of a fine-to-medium coarse basic texture. There may be some heterogeneity because of the hypoechoic areas of hemorrhage or necrosis, which were not seen in our case. A distinctive ‘ring sign’ may be seen in typical intrarenal CMN 14, as also seen in our patient. Although most cases of CMN have been diagnosed postnatally, with advances in the imaging technology, an increasing number of cases are being detected on antenatal scans 15. Irsutti et al. 16 have discussed the antenatal USG and MRI features of CMN.

Childhood renal tumors were classified according to the ‘Stockholm classification’, in which CMN is included in low-risk group and staged as per other renal tumors into ST1-5 (SIOP staging).

Cystic change with hemorrhage and necrosis has been reported to be of significance in determining the prognosis of mesoblastic nephromas. Whereas Garbyal et al.17 consider it to be of adverse significance, the cystic CMN reported by Murthi et al.18 had a good outcome. Both patients in our series had cystic change within the tumor. Both of them with small cysts had difficult excision, but no intraoperative tumor spillage. Therefore, apart from contributing adversely to the tumor dissection, the presence of cysts and hemorrhage most probably does not have any prognostic value.

Recent studies have shown that the classic and cellular variants have genetic differences. Only the cellular variant shows translocation (12; 15) (p13; q25), which leads to the ETV6-NTRK3 gene fusion. There have been varied findings in mixed subtypes 19.

Surgery is the primary modality of treatment. The role of chemotherapy for the treatment of CMNs is controversial. It is well appreciated that the definitive management for a CMN is a surgical excision, with disease-free margins. In the event of a recurrence or with an inoperable tumor, chemotherapy may be beneficial. Kulkarni et al.20 have stated the role of diagnostic cytopathology in differentiating mesoblastic nephroma from other renal tumors.


CMN, though rare, should be considered in differential diagnosis of renal mass occurring in infancy. Hypertension should be looked for and stabilized before surgical intervention for best outcome. Diagnosis is made best by CT/MRI. Surgery is curative, but long-term follow-up is needed.


Conflicts of interest

There are no conflicts of interest.


1. Haddad B, Haziza J, Touboul C, Abdellilah M, Uzan S, Paniel BJ. The congenital mesoblastic nephroma: a case report of prenatal diagnosis. Fetal Diagn Ther 1996; 11:61–66.
2. Glick RD, Hicks MJ, Nuchtern JG, Wesson DE, Olutoye OO, Cass DL. Renal tumors in infants less than 6 months of age. J Pediatr Surg 2004; 39:522–525.
3. Bolande RP, Brough AJ, Izant RJ Jr. Congenital mesoblastic nephroma of infancy. A report of eight cases and the relationship to Wilms’ tumor. Pediatrics 1967; 40:272–278.
4. Ahmed HU, Arya M, Levitt G, Duffy PG, Sebire NJ, Mushtaq I. Part II: treatment of primary malignant non-Wilms’ renal tumours in children. Lancet Oncol 2007; 8:842–848.
5. Ahmed HU, Arya M, Levitt G, Duffy PG, Mushtaq I, Sebire NJ. Part I: primary malignant non-Wilms’ renal tumours in children. Lancet Oncol 2007; 8:730–737.
6. Gruver AM, Hansel DE, Luthringer DJ, MacLennan GT. Congenital mesoblastic nephroma. J Urol 2010; 183:1188–1189.
7. Berdon WE, Wigger HJ, Baker DH. Fetal renal hamartoma: a benign tumor to be distinguished from Wilms’ tumor. Report of 3 cases. Am J Roentgenol Radium Ther Nucl Med 1973; 118:18–27.
8. Furtwaengler R, Reinhard H, Leuschner I, Schenk JP, Goebel U, Claviez A, et al.Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH) Nephroblastoma Study Group. Mesoblastic nephroma: a report from the Gesellschaft fur Pädiatrische Onkologie und Hämatologie (GPOH). Cancer 2006; 106:2275–2283.
9. England RJ, Haider N, Vujanic GM, Kelsey A, Stiller CA, Pritchard-Jones K, Powis M. Mesoblastic nephroma: a report of the United Kingdom Children’s Cancer and Leukaemia Group (CCLG). Pediatr Blood Cancer 2011; 56:744–748.
10. Portugal R, Barroca H. Clear cell sarcoma, cellular mesoblastic nephroma and metanephric adenoma: cytological features and differential diagnosis with Wilms tumour. Cytopathology 2008; 19:80–85.
11. Sebire NJ, Vujanic GM. Paediatric renal tumours: recent developments, new entities and pathological features. Histopathology 2009; 54:516–528.
12. Miller OF, Kolon TF. Hyperreninemia and congenital mesoblastic nephroma: case report and review of the literature. Urology 2000; 55:775.
13. Ko SM, Kim MJ, Im YJ, Park KI, Lee MJ. Cellular mesoblastic nephroma with liver metastasis in a neonate: prenatal and postnatal diffusion-weighted MR imaging. Korean J Radiol 2013; 14:361–365.
14. Kelner M, Droullé P, Didier F, Hoeffel JC. The vascular ‘ring’ sign in mesoblastic nephroma: report of two cases. Pediatr Radiol 2003; 33:123–128.
15. Surh JS, Hwang SA, Park HN, Jeon SJ, Kim SY. Prenatal diagnosis of mesoblastic nephroma: a case report. Womens Med 2011; 4:11–14.
16. Irsutti M, Puget C, Baunin C, Duga I, Sarramon MF, Guitard J. Mesoblastic nephroma: prenatal ultrasonographic and MRI features. Pediatr Radiol 2000; 30:147–150.
17. Garbyal RS, Aryya NC, Gangopadhya AN, Gupta DK. Cystic atypical mesoblastic nephroma. Pediatr Surg Int 2002; 18:123–127.
18. Murthi GV, Carachi R, Howatson A. Congenital cystic mesoblastic nephroma. Pediatr Surg Int 2003; 19:109–111.
19. Watanabe N, Haruta M, Soejima H, Fukushi D, Yokomori K, Nakadate H, et al.. Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or mixed type. Genes Chromosomes Cancer 2007; 46:929–935.
20. Kulkarni MP, Gosavi AV, Anvikar AR, Ramteerthakar NA, Lanjewar DN. Cytodiagnosis of congenital mesoblastic nephroma: a case report. Diagn Cytopathol 2013; 41:234–238.
© 2014 Annals of Pediatric Surgery